Acquired by Combinati was acquired by Thermo Fisher Scientific in 2021, indicating a strong exit and integration with a major life sciences player. This suggests potential alignment opportunities with Thermo Fisher teams or leveraging Thermo Fisher channels for future sales and collaboration.

Digital PCR Focus The company specializes in a simple, robust digital PCR platform for absolute quantification and biomarker tracking, offering a potentially attractive value proposition for labs seeking accurate quantification with minimal waste. This signals a sales angle around high-precision diagnostics and longitudinal studies.

Early Stage Current revenue is under one million with total funding around five to six million, and a very small team. This suggests a high-urgency sales motion, potential for pilot programs, and strategic partnerships to accelerate market adoption.

Global Accessibility Aimed at democratizing digital PCR for researchers worldwide via a compact instrument and consumables, presenting opportunities to expand through academic, clinical, and contract research organizations that value scalable, user-friendly technology.

Strategic Fit As part of Thermo Fisher’s portfolio, there may be cross-sell or integration opportunities with existing dPCR-related workflows, sample preparation, and analytics tools, offering a path to broader adoption and channel-driven sales.